Repligen 

$167.60
45
-$2.01-1.19% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
169.5
Day Low
165
52W High
188.73
52W Low
100.99
Volume
806,064
Avg. Volume
1,123,465
Mkt Cap
9.46B
P/E Ratio
158.51
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.35
0.41
0.48
0.54
Expected EPS
0.46258
Actual EPS
N/A

Financials

6.62%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
738.26MRevenue
48.89MNet Income

Analyst Ratings

166.64Average Price Target
The highest estimate is 208.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGEN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Danaher
DHR
Mkt Cap151.89B
Danaher Corporation operates in the life sciences field, offering products and services similar to Repligen's bioprocessing technologies, making them direct competitors in the biotech and pharmaceutical manufacturing sector.
Thermo Fisher Scientific
TMO
Mkt Cap230.05B
Thermo Fisher Scientific provides a range of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics, overlapping with Repligen's offerings in bioprocessing and biomanufacturing.
Bio-Rad Laboratories
BIO
Mkt Cap10.37B
Bio-Rad Laboratories offers products and services in the field of life science research and clinical diagnostics, competing with Repligen in the supply of bioprocessing equipment and consumables.
Sartorius
SARTF
Mkt Cap14.69B
Sartorius AG competes with Repligen in the bioprocessing market, offering similar bioprocess solutions including filters and single-use systems for the biopharmaceutical industry.
Illumina
ILMN
Mkt Cap32.55B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which, while more focused on genomics, competes with Repligen in the broader biotech research and development space.
Casey`s General Stores
CASY
Mkt Cap27.96B
Catalent, Inc. offers delivery technologies and development solutions for drugs, biologics, and consumer health products, competing with Repligen in the biomanufacturing and bioprocessing sectors.
Avantor
AVTR
Mkt Cap9.86B
Avantor, Inc. provides products and services to the life sciences and advanced technology industries, competing with Repligen in the supply of materials and consumables for bioprocessing.
Repligen
RGEN
Mkt Cap9.95B
Regeneron Pharmaceuticals, while primarily a biotechnology company focused on developing and commercializing pharmaceuticals, competes with Repligen through its demand and innovation in bioprocessing technologies for drug development.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc., as a biopharmaceutical company, indirectly competes with Repligen by developing bioprocessing technologies in-house for their drug development, representing competition for market share in bioprocessing solutions.
GE HealthCare Technologies
GEHC
Mkt Cap32.4B
GE Healthcare provides medical technology and digital solutions, including bioprocessing technologies that compete with Repligen's offerings in the life sciences and biopharmaceutical manufacturing sectors.

About

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Show more...
CEO
Olivier Loeillot
Employees
2000
Country
United States
ISIN
US7599161095
WKN
000870980

Listings

0 Comments

Share your thoughts

FAQ

What is Repligen stock price today?
The current price of RGEN is $167.60 USD — it has decreased by -1.19% in the past 24 hours. Watch Repligen stock price performance more closely on the chart.
What is Repligen stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Repligen stocks are traded under the ticker RGEN.
Is Repligen stock price growing?
RGEN stock has fallen by -4.92% compared to the previous week, the month change is a +5.68% rise, over the last year Repligen has showed a +34.55% increase.
What is Repligen market cap?
Today Repligen has the market capitalization of 9.46B
When is the next Repligen earnings date?
Repligen is going to release the next earnings report on November 03, 2026.
What were Repligen earnings last quarter?
RGEN earnings for the last quarter are 0.54 USD per share, whereas the estimation was 0.45 USD resulting in a +20.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Repligen revenue for the last year?
Repligen revenue for the last year amounts to 738.26M USD.
What is Repligen net income for the last year?
RGEN net income for the last year is 48.89M USD.
How many employees does Repligen have?
As of September 05, 2026, the company has 2,000 employees.
In which sector is Repligen located?
Repligen operates in the Health & Wellness sector.
When did Repligen complete a stock split?
Repligen has not had any recent stock splits.
Where is Repligen headquartered?
Repligen is headquartered in WALTHAM, United States.